Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spinal Cord Stimulation With Integrated Pain Psychology for Pediatric Refractory Neuropathic Pain: A Case Report.

A&A practice·2026
Same author

Retrospective Assessment of Adjacent Fracture Risks in Vertebroplasty, Kyphoplasty, and Bone-Tumor Radiofrequency Ablation.

Pain practice : the official journal of World Institute of Pain·2026
Same author

Leveraging artificial intelligence to optimize neuromodulation in the treatment of patients with chronic pain.

Frontiers in pain research (Lausanne, Switzerland)·2026
Same author

The Current Scope of Pain Medicine Fellowships: A Cross-Sectional Survey Study of Trainees, Directors, and Employers on Shaping Future Leaders.

Journal of pain research·2026
Same author

Match Program Signaling in Pain Medicine Fellowship Applications: Association with Interview Outcomes and Implications for a Shrinking Applicant Pipeline.

Pain physician·2026
Same author

Risk Factors of Chemotherapy-Induced Painful Peripheral Neuropathy: A Retrospective Study from A Single Cancer Center.

Pain physician·2026
Same journal

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

A Quantitative Sensory Testing Paradigm to Obtain Measures of Pain Processing in Patients Undergoing Breast Cancer Surgery
07:14

A Quantitative Sensory Testing Paradigm to Obtain Measures of Pain Processing in Patients Undergoing Breast Cancer Surgery

Published on: January 18, 2018

Buprenorphine for Cancer Pain: Evidence, Guidelines, and Clinical Rationale for Early Use.

Marcin Chwistek1, Leigh Kinczewski1, Sorin Buga2

  • 11Department of Hematology and Oncology, Fox Chase Cancer Center/Temple University Health, Philadelphia, PA.

Journal of the National Comprehensive Cancer Network : JNCCN
|June 15, 2026
PubMed
Summary
This summary is machine-generated.

Buprenorphine offers safer cancer pain management than traditional opioids, reducing harms. Early adoption can improve patient safety and quality of life.

Related Experiment Videos

Last Updated: Jun 17, 2026

A Quantitative Sensory Testing Paradigm to Obtain Measures of Pain Processing in Patients Undergoing Breast Cancer Surgery
07:14

A Quantitative Sensory Testing Paradigm to Obtain Measures of Pain Processing in Patients Undergoing Breast Cancer Surgery

Published on: January 18, 2018

Area of Science:

  • Oncology
  • Pain Management
  • Pharmacology

Background:

  • Long-term opioid therapy (LTOT) is increasingly used in cancer care, leading to concerns about opioid-related harms.
  • Buprenorphine, a partial agonist, presents unique advantages over full agonist opioids (FAOs) for managing cancer pain (CP).
  • Despite its benefits, buprenorphine remains underutilized in oncology pain management.

Purpose of the Study:

  • To review the clinical rationale, evidence, and practical considerations for using buprenorphine in cancer pain management.
  • To examine buprenorphine's pharmacodynamics, dosing, safety, and potential to mitigate opioid complications.
  • To discuss barriers to buprenorphine implementation and suggest strategies for broader clinical integration.

Main Methods:

  • Synthesis of pharmacologic research, clinical trials, and guideline updates.
  • Review of expert consensus and NCCN Adult Cancer Pain Guideline Panel recommendations.
  • Examination of buprenorphine's efficacy and safety in vulnerable populations.

Main Results:

  • Buprenorphine provides comparable analgesia to FAOs with reduced risks of respiratory depression, opioid-induced hyperalgesia, hormonal disruption, and neurocognitive impairment.
  • Buprenorphine may mitigate neuroadaptive changes from LTOT, preserving efficacy and improving function.
  • Multiple formulations and flexible dosing support personalized CP management, but barriers like prescriber hesitancy and stigma persist.

Conclusions:

  • Buprenorphine is an underutilized yet viable option for managing cancer pain, especially when LTOT is anticipated.
  • Broader integration requires improved guidelines, clinician education, and policy reform.
  • Proactive buprenorphine use can enhance safety, function, and quality of life for oncology patients.